Novo Nordisk Buyback Total Nears DKK 10.25 Billion as Deutsche Bank and J.P. Morgan Diverge

Novo Nordisk closed at EUR 34.06, up 2.8%, as Deutsche Bank cut its target and J.P. Morgan held Neutral, with oral Wegovy demand in focus.

Shares of Novo Nordisk finished Wednesday's session at EUR 34.06, up 2.8%, a move that lacked any single corporate catalyst and left the market to weigh the Danish drugmaker's underlying trajectory. The advance offers some relief for a stock trading roughly 38% below its 52-week high, though it has done little to settle the debate over whether the bounce marks the start of a recovery or merely a technical rebound.

Analyst opinion is split down the middle. Deutsche Bank Research cut its price target on the shares to DKK 225 from DKK 245, keeping a Sell rating, according to media reports. The bank flagged the latest EASD conference results as a mildly negative factor. J.P. Morgan struck a more constructive tone on Monday, maintaining a Neutral rating with a DKK 275 target and pointing to a potentially brighter path ahead.

Oral Wegovy Emerges as the Swing Factor

Beneath those differing verdicts sits one question: how much real demand exists for oral Wegovy. J.P. Morgan argued Monday that better-than-expected uptake of the tablet could meaningfully lift third-quarter results, giving the company valuable breathing room. Should that momentum fail to materialize, the company's lofty growth assumptions come under strain. The product's commercial performance is shaping up as the single lever on which the next valuation call rests.

In the bull case, Novo Nordisk delivers a positive surprise for the third quarter, and J.P. Morgan sees room for a full-year guidance raise if oral Wegovy demand outpaces estimates. Such an upward revision would ease the recent downward pressure and could quickly restore investor confidence.

Buybacks Keep Running

Supporting that scenario is the company's steady stream of repurchases. Novo Nordisk said Monday it bought back 1,225,000 B shares for DKK 307.4 million between September 28 and October 2. That sits within an DKK 11.2 billion program forming part of a broader buyback of up to DKK 15 billion. The ongoing purchases tighten the supply of freely traded stock and signal management's faith in the business's earnings power.

Updated figures released Monday put the cumulative total since early February at 36,604,179 B shares acquired through the October 2 cut-off, worth DKK 10,247,270,869.

Pipeline Bets and a Regulatory Snag

On the development front, Novo Nordisk is paying USD 300 million upfront for rights to drug candidate HRS-1596 outside mainland China, Hong Kong, Macao and Taiwan, broadening its pipeline. The licensing deal with Hengrui was struck more than a month ago, and the shares have fallen 27.9% since.

Not everything is moving smoothly. The FDA has extended its review of Denecimig for hemophilia A after requiring fixes at a manufacturing site. The agency raised no concerns about efficacy or safety but gave no new decision timeline. Novo Nordisk still targets a US launch in the first half of 2027 and left its 2026 financial outlook untouched.

Fresh real-world data on Wegovy and Ozempic, presented about a week ago, have added 1.6% to the stock since. A post-hoc analysis of the STEP-UP trial found Wegovy normalized liver fat in 23 of 26 patients who began with elevated levels, reinforcing the GLP-1 agent's therapeutic reach beyond weight loss. Market watchers read such findings as an important signal for defending market share amid intensifying competition. Even so, industry experts counsel caution, noting that conference discussions have sent mixed signals about the company's medium-term pipeline.

The Level That Matters

As long as support at the 52-week low of EUR 30.25 holds, the chance of stabilization remains intact. A collapse in confidence in the revenue trajectory ahead of quarterly results, however, could trigger another test of that floor, narrowing investors' room to maneuver to that single mark. The next hard catalyst is the third-quarter report, which will reveal whether J.P. Morgan's optimism or Deutsche Bank's caution carries the day. Until those numbers land, the posture is one of tactical restraint.